Trial Profile
An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 May 2023
Price :
$35
*
At a glance
- Drugs Vibegron (Primary) ; Tolterodine
- Indications Overactive bladder
- Focus Registrational; Therapeutic Use
- Acronyms EMPOWUR
- Sponsors Pierre Fabre; Urovant Sciences
- 22 May 2023 According to Pierre Fabre media release, based on positive data from this study, EU marketing authorization application procedure for Vibegron in overactive bladder have been started.
- 01 Jun 2022 Results of a sub-group analysis of vibegron for treatment of patients with dry and wet overactive bladder published in the International Journal of Clinical Practice
- 19 Apr 2022 According to an Urovant Sciences media release, data from the study was published in the Journal of Urology in May 2021.